PharmaShots Weekly Snapshot (October 28 – November 01, 2019)

1. Medtronic Reports MHLW’s Shonin Approval and Launches Valiant Navion Thoracic Stent Graft System in Japan

Published: Oct 31, 2019 | Tags: Medtronic, Reports, MHLW, Shonin Approval, Launches, Valiant Navion Thoracic Stent Graft System, Japan 

2. Beam Therapeutics Signs Exclusive License Agreement with Prime Medicine for Prime Editing Technology

Published: Oct 31, 2019 | Tags: Beam Therapeutics, Signs, Exclusive, License Agreement, Prime Medicine, Prime Editing Technology

3.  Vertex Reports Results of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Two P-III Studies for Cystic Fibrosis

Published: Oct 31, 2019 | Tags: Vertex, Reports, Results, Trikafta, elexacaftor, tezacaftor, ivacaftor, P-III Studies, Cystic Fibrosis 

4.  AbbVie Reports Results of Rinvoq (upadacitinib) in P-III SELECT-PsA 2 Study for Psoriatic Arthritis

Published: Oct 30, 2019 | Tags: AbbVie, Reports, Results, Rinvoq, upadacitinib, P-III, SELECT-PsA 2, Study, Psoriatic Arthritis

6.  Novartis Reports Results of Cosentyx (secukinumab) in Head to Head P-III EXCEED Study for Psoriatic Arthritis

Published: Nov 01, 2019 | Tags: Novartis, Reports, Results, Cosentyx, secukinumab, Head to Head, P-III, EXCEED Study, Psoriatic Arthritis

7.  Amgen Acquires Stake in BeiGene to Expand its Oncology Portfolio in China

Published: Oct 31, 2019 | Tags: Amgen, Signs, Strategic, Collaboration, BeiGene, Expand, Oncology Portfolio, China

8. Janssen’s Darzalex (daratumumab) Combination Regimen Receives Health Canada Approval for Transplant Ineligible Patients with Multiple Myeloma

Published:  Oct 30, 2019 | Tags: Janssen, Darzalex, daratumumab, Combination, Regimen, Receives, Health Canada, Approval, Transplant Ineligible Patients, Multiple Myeloma

9. Roche Signs a Development and Commercialization Agreement with Dicerna for its DCR-HBVS to Treat Chronic Hepatitis B Virus Infection

Published: Oct 31, 2019 | Tags: Roche, Signs, Development, Commercialization, Agreement, Dicerna, DCR-HBVS, Chronic Hepatitis B Virus Infection

10.  AliveCor and Huami Collaborate to Bring the Next Generation ECG Wearables Devices

Published: Oct 30, 2019 | Tags: AliveCor, Huami, Collaborate, Bring, Next Generation, Medical Wearables Devices

11.  Johnson & Johnson Vision Launches TECNIS Eyhance Monofocal Intraocular Lens for Post Cataract Surgery Patients in India

Published: Oct 31, 2019 | Tags: Johnson & Johnson Vision, Launches, TECNIS Eyhance, Monofocal Intraocular Lens, Post Cataract Surgery Patients, India

12.  Astellas Signs an Exclusive License Agreement with Pandion to Deliver Immunomodulators for Autoimmune Diseases of the Pancreas

Published: Oct 30, 2019 | Tags: Astellas, Signs, Exclusive, License Agreement, Pandion, Deliver, Immunomodulators, Autoimmune Diseases, Pancreas

13.  Pear Therapeutics Signs an Agreement with Ironwood to Assess Prescription Digital Therapeutics for GI Indications

Published: Oct 30, 2019 | Tags: Pear Therapeutics, Signs, Agreement, Ironwood, Assess, Prescription Digital Therapeutics, GI Indications

14.  Biogen and Alkermes’ Vumerity (diroximel fumarate) Receive FDA’s Approval for Multiple Sclerosis

Published: Oct 30, 2019 | Tags: Biogen, Alkermes, Vumerity, diroximel fumarate, Receive, FDA, Approval, Multiple Sclerosis

15.  LEO Pharma Signs an Option Agreement with Ubiquigent to Access its Two Novel Therapies

Published: Oct 30, 2019 | Tags: LEO Pharma, Signs, Option Agreement, Ubiquigent, Access, Two, Novel Therapies

16.  Novartis Reports FDA’s Hold on P-I/II Intrathecal Study Evaluating Zolgensma/AVXS-101 (onasemnogene abeparvovec-xioi) for Spinal Muscular Atrophy Type 2

Published: Oct 30, 2019 | Tags: Novartis, Reports, FDA, Hold, P-I/II, Intrathecal, Zolgensma/AVXS-101, onasemnogene abeparvovec-xioi, Spinal Muscular Atrophy Type 2

17.  Roche Reports EMA and FDA’s Acceptance of Marketing Application for Satralizumab to Treat Neuromyelitis Optica Spectrum Disorder

Published: Oct 30, 2019 | Tags: Roche, Reports, EMA, FDA, Acceptance, Marketing Application, Satralizumab, Treat, Neuromyelitis Optica Spectrum Disorder

18.  AstraZeneca Divests Rights of Seroquel and Seroquel XR to Cheplapharm in Europe and Russia

Published: Oct 30, 2019 | Tags: AstraZeneca, Divests, Rights, Seroquel, Seroquel XR, Cheplapharm, Europe, Russia

19.  GSK’s Benlysta (belimumab, IV) Receives EC’s Approvals as the First Biologic to Treat Lupus in Children

Published: Oct 30, 2019 | Tags: GSK, Intravenous, Benlysta, belimumab, Receives, EC, Approvals, First Biologic, Treat, Lupus, Children

20.  Boehringer Ingelheim Collaborates with The Defeat-NCD Partnership to Tackle the Impacts of Non-Communicable Diseases

Published: Oct 21, 2019 | Tags: Boehringer Ingelheim, Collaborates, The Defeat-NCD Partnership, Tackle, Impacts, Non-Communicable Diseases

21.  Astellas’ ASP1128 Receives the US FDA’s Fast Track Designation for Patients at High Risk of Acute Kidney Injury

Published: Oct 22, 2019 | Tags: Astellas, ASP1128, Receives, US, FDA, Fast Track Designation, Patients, High Risk, Acute Kidney Injury

22.  MorphoSys and Galapagos in Collaboration with Novartis Terminate Clinical Development of MOR106 in Atopic Dermatitis

Published: Oct 21, 2019 | Tags: MorphoSys, Galapagos, Collaboration, Novartis, Terminate, Clinical Development, MOR106, Atopic Dermatitis

23.  GSK Reports Results of M72/AS01E in P-IIb Study for the Prevention of Pulmonary Tuberculosis Disease

Published: Oct 21, 2019 | Tags:  GSK, Reports, Results, M72/AS01E, P-IIb, Prevention, Pulmonary Tuberculosis Disease

24.  Pfizer’s Bavencio (avelumab) + Axitinib Dual Regimen Receive EC’s Approval as 1L Treatment for Advanced Renal Cell Carcinoma

Published: Oct 21, 2019 | Tags: Pfizer, Bavencio, Avelumab, Axitinib, Dual Regimen, Receives, EC, Approval,1L treatment, Advanced Renal Cell Carcinoma

25. AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer

Published: Oct 21, 2019 | Tags: AstraZeneca, Reports, Results, Imfinzi, durvalumab, Tremelimumab, P-III, POSEIDON, Study, 1L, Treatment, Stage IV, Non-Small Cell Lung Cancer

26. Gilead Collaborates with Glympse Bio to Utilize Biomarker Technology in NASH Clinical Program

Published: Oct 21, 2019 | Tags: Gilead, Collaborates, Glympse Bio, Utilize, Biomarker Technology, NASH Clinical Program